HOME ABOUT PIPELINE BUSINESS DEVELOPMENT CAREERS CONTACT CUTX-101 (Copper Histidinate) Cyprium Therapeutics, Inc. (https://www.cypriumtx.com/), with support from Sentynl, is developing CUTX-101 (Copper Histidinate) to restore copper homeostasis and maintain copper levels in patients with Menkes disease and related disorders. CUTX-101 is a subcutaneous injectable formulation of Copper Histidinate manufactured under current Good Manufacturing Practice (cGMP) that is intended to improve tolerability due to its physiological pH, and to bypass the oral absorption of copper, which is impaired in patients with Menkes disease. In the Phase 1/2 clinical study conducted at NICHD, early treatment of Menkes patients with CUTX-101 led to an improvement in neurodevelopmental outcomes and survival. A Phase 3 study of CUTX-101 is ongoing at NICHD. A natural history study is being completed to collect data on Menkes disease patients who have not been treated with copper supplements. Data from this natural history study will serve as a historical control to demonstrate the efficacy and safety of CUTX-101. CUTX-101 has been granted orphan drug designation by the US Food and Drug Administration (FDA). FDA granted Fast Track Designation, Rare Pediatric Disease Designation and Breakthrough Therapy Designation to CUTX-101. In July 2020, European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on the Orphan Medicinal Product Designation for CUTX-101. © 2015-2021 by Sentynl Therapeutics, Inc. All Rights Reserved. Terms of Use Privacy Report an Adverse Event Corporate Compliance

HOME ABOUT PIPELINE BUSINESS DEVELOPMENT CAREERS CONTACT Join our Team! We are always looking for exceptional candidates to join our growing team. If you are interested in working with us, please complete this form to help us understand your interests. Be sure to include a copy of your most recent resume in Adobe Acrobat (.pdf) or Microsoft Word (.doc or .docx) format. Key positions we’re currently hiring are: · Senior Counsel, Director of Compliance © 2015-2021 by Sentynl Therapeutics, Inc. All Rights Reserved. Terms of Use Privacy Report an Adverse Event Corporate Compliance

HOME ABOUT PIPELINE BUSINESS DEVELOPMENT CAREERS CONTACT General Contact For general inquiries, please use the form on the right to reach us. For Business Development, please see the Business Development link at the top of this page. To report an adverse event or if you have a Medical Affairs question, please dial 877-767-2656. Name * First Name Last Name Email Address * Phone (###) ### #### Subject * Message * © 2015-2021 by Sentynl Therapeutics, Inc. All Rights Reserved. Terms of Use Privacy Report an Adverse Event Corporate Compliance